Total Payments
$31,505
2024 Payments
$1,906
Companies
38
Transactions
601
Medicare Patients
1,449
Medicare Billing
$140,055
Payment Breakdown by Category
Research$21,566 (68.5%)
Food & Beverage$9,836 (31.2%)
Education$66.94 (0.2%)
Gifts$36.66 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21,566 | 5 | 68.5% |
| Food and Beverage | $9,836 | 593 | 31.2% |
| Education | $66.94 | 2 | 0.2% |
| Gift | $36.66 | 1 | 0.1% |
Payments by Type
Research
$21,566
5 transactions
General
$9,939
596 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $21,566 | 5 | $0 (2023) |
| ABBVIE INC. | $2,859 | 171 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,456 | 98 | $0 (2024) |
| Janssen Biotech, Inc. | $864.40 | 44 | $0 (2024) |
| PFIZER INC. | $593.02 | 39 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $442.94 | 25 | $0 (2024) |
| Celgene Corporation | $376.95 | 19 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $326.81 | 18 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $314.76 | 21 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $248.60 | 17 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,906 | 93 | ABBVIE INC. ($601.97) |
| 2023 | $1,593 | 89 | ABBVIE INC. ($348.24) |
| 2022 | $2,096 | 126 | ABBVIE INC. ($587.52) |
| 2021 | $8,777 | 95 | Eli Lilly and Company ($7,231) |
| 2020 | $13,770 | 39 | Eli Lilly and Company ($13,155) |
| 2019 | $1,626 | 33 | Eli Lilly and Company ($1,109) |
| 2018 | $820.93 | 54 | AbbVie, Inc. ($228.28) |
| 2017 | $916.99 | 72 | Valeant Pharmaceuticals North America LLC ($248.60) |
All Payment Transactions
601 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $9.51 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $8.22 | General |
| Category: Gastroenterology | ||||||
| 10/23/2024 | Braintree Laboratories, Inc. | SUTAB (Drug), SUFLAVE | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: GI COLON PREP | ||||||
| 10/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/17/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/11/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.55 | General |
| Category: Immunology | ||||||
| 10/02/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: LIVER DISEASE | ||||||
| 09/25/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Immunology | ||||||
| 09/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/12/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $28.66 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/11/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/05/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/05/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: Gastroenterology | ||||||
| 09/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Immunology | ||||||
| 08/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Immunology | ||||||
| 08/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.73 | General |
| 08/15/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.86 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $21,496 | 4 |
| A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $70.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 291 | 307 | $108,102 | $24,878 |
| 2022 | 11 | 333 | 355 | $131,653 | $34,278 |
| 2021 | 11 | 361 | 401 | $137,688 | $37,327 |
| 2020 | 12 | 464 | 504 | $185,663 | $43,571 |
Total Patients
1,449
Total Services
1,567
Medicare Billing
$140,055
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 81 | 93 | $15,330 | $5,610 | 36.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 29 | 29 | $29,957 | $5,145 | 17.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 83 | 83 | $16,600 | $4,941 | 29.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 21 | 21 | $16,800 | $2,707 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 27 | $5,915 | $1,974 | 33.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $10,200 | $1,510 | 14.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 13 | $2,925 | $1,097 | 37.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $7,575 | $1,052 | 13.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 14 | $2,800 | $841.68 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 71 | $14,732 | $6,427 | 43.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 35 | 35 | $36,155 | $6,365 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $11,689 | $4,523 | 38.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 28 | 29 | $23,200 | $4,033 | 17.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 30 | $8,007 | $3,447 | 43.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 41 | 41 | $8,200 | $2,672 | 32.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 45 | $6,750 | $2,575 | 38.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 14 | $3,150 | $1,105 | 35.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 14 | 14 | $7,070 | $1,083 | 15.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $9,100 | $1,062 | 11.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 18 | $3,600 | $985.93 | 27.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 82 | 104 | $13,977 | $6,978 | 49.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 32 | 32 | $33,056 | $5,981 | 18.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 75 | 75 | $15,000 | $5,386 | 35.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 39 | $7,585 | $3,609 | 47.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 23 | 23 | $19,550 | $3,352 | 17.1% |
About Dr. Jyothi Mann, MD
Dr. Jyothi Mann, MD is a Gastroenterology healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881701928.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jyothi Mann, MD has received a total of $31,505 in payments from pharmaceutical and medical device companies, with $1,906 received in 2024. These payments were reported across 601 transactions from 38 companies. The most common payment nature is "" ($21,566).
As a Medicare-enrolled provider, Mann has provided services to 1,449 Medicare beneficiaries, totaling 1,567 services with total Medicare billing of $140,055. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Greensboro, NC
- Active Since 08/24/2006
- Last Updated 10/14/2008
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1881701928
Products in Payments
- XIFAXAN (Drug) $990.94
- LINZESS (Drug) $785.80
- VIBERZI (Drug) $616.21
- XELJANZ (Drug) $577.31
- TRULANCE (Drug) $461.52
- REMICADE (Biological) $414.18
- RINVOQ (Biological) $394.16
- ZEPOSIA (Drug) $388.34
- HUMIRA (Biological) $355.32
- ENTYVIO (Biological) $295.33
- STELARA (Biological) $291.28
- Linzess (Drug) $289.36
- Humira (Biological) $253.57
- CLENPIQ (Drug) $248.22
- IBSRELA (Drug) $246.79
- Creon (Drug) $231.22
- Trulance (Drug) $226.40
- DUPIXENT (Biological) $211.56
- SKYRIZI (Biological) $209.52
- OCALIVA (Drug) $200.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Greensboro
Dr. Patrick Hung, Md, MD
Gastroenterology — Payments: $40,240
Gastroenterology $40,240
Vincent Schooler, Md, MD
Gastroenterology — Payments: $4,224
Gastroenterology $4,224
Marc Magod, Md, MD
Gastroenterology — Payments: $4,164
Gastroenterology $4,164
Dr. Parag Brahmbhatt, M.d, M.D
Gastroenterology — Payments: $4,061
Gastroenterology $4,061
William Outlaw, Md, MD
Gastroenterology — Payments: $3,811
Gastroenterology $3,811
Dr. Claire Vreeland, D.o, D.O
Gastroenterology — Payments: $2,364
Gastroenterology $2,364